Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.

Weishaar KM, Ehrhart EJ, Avery AC, Charles JB, Elmslie RE, Vail DM, London CA, Clifford CA, Eickhoff JC, Thamm DH.

J Vet Intern Med. 2018 Jan;32(1):394-405. doi: 10.1111/jvim.14889. Epub 2017 Nov 30.

2.

Efficacy of Radiation Therapy for the Treatment of Sialocele in Dogs.

Poirier VJ, Mayer-Stankeová S, Buchholz J, Vail DM, Kaser Hotz B.

J Vet Intern Med. 2018 Jan;32(1):107-110. doi: 10.1111/jvim.14868. Epub 2017 Nov 13.

3.

Pilot study of safety and feasibility of DNA microseeding for treatment of spontaneous canine melanoma.

Zuleger CL, Kang C, Ranheim EA, Kurzman ID, Macklin MD, Newton MA, Wolchok JD, Vail DM, Eriksson E, Albertini MR.

Vet Med Sci. 2017 May 22;3(3):134-145. doi: 10.1002/vms3.65. eCollection 2017 Aug.

4.

Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses.

Saba CF, Vickery KR, Clifford CA, Burgess KE, Phillips B, Vail DM, Wright ZM, Morges MA, Fan TM, Thamm DH.

Vet Comp Oncol. 2018 Mar;16(1):E76-E82. doi: 10.1111/vco.12337. Epub 2017 Sep 11.

PMID:
28891260
5.

Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.

Laver T, London CA, Vail DM, Biller BJ, Coy J, Thamm DH.

Vet Comp Oncol. 2018 Mar;16(1):E23-E29. doi: 10.1111/vco.12328. Epub 2017 Jun 15.

PMID:
28621057
6.

Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma.

Thamm DH, Vail DM, Post GS, Fan TM, Phillips BS, Axiak-Bechtel S, Elmslie RS, Klein MK, Ruslander DA.

J Vet Intern Med. 2017 May;31(3):872-878. doi: 10.1111/jvim.14700. Epub 2017 Apr 3.

7.

Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.

Pellin MA, Wouda RM, Robinson K, Tsimbas K, Kurzman ID, Biller BJ, Vail DM.

Vet Comp Oncol. 2017 Sep;15(3):919-931. doi: 10.1111/vco.12232. Epub 2016 May 5.

PMID:
27146577
8.

Computed Tomography Imaging of Solid Tumors Using a Liposomal-Iodine Contrast Agent in Companion Dogs with Naturally Occurring Cancer.

Ghaghada KB, Sato AF, Starosolski ZA, Berg J, Vail DM.

PLoS One. 2016 Mar 31;11(3):e0152718. doi: 10.1371/journal.pone.0152718. eCollection 2016.

9.

Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology.

LeBlanc AK, Breen M, Choyke P, Dewhirst M, Fan TM, Gustafson DL, Helman LJ, Kastan MB, Knapp DW, Levin WJ, London C, Mason N, Mazcko C, Olson PN, Page R, Teicher BA, Thamm DH, Trent JM, Vail DM, Khanna C.

Sci Transl Med. 2016 Feb 3;8(324):324ps5. doi: 10.1126/scitranslmed.aaf0746. Review. No abstract available.

PMID:
26843188
11.

A Review of Paclitaxel and Novel Formulations Including Those Suitable for Use in Dogs.

Khanna C, Rosenberg M, Vail DM.

J Vet Intern Med. 2015 Jul-Aug;29(4):1006-12. doi: 10.1111/jvim.12596. Review.

12.

Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.

Burton JH, Venable RO, Vail DM, Williams LE, Clifford CA, Axiak-Bechtel SM, Avery AC, Thamm DH.

J Vet Intern Med. 2015 Jul-Aug;29(4):1098-104. doi: 10.1111/jvim.13573. Epub 2015 Jun 25.

13.

Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.

Gardner HL, London CA, Portela RA, Nguyen S, Rosenberg MP, Klein MK, Clifford C, Thamm DH, Vail DM, Bergman P, Crawford-Jakubiak M, Henry C, Locke J, Garrett LD.

BMC Vet Res. 2015 Jun 11;11:131. doi: 10.1186/s12917-015-0446-1.

14.

Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.

London CA, Gardner HL, Mathie T, Stingle N, Portela R, Pennell ML, Clifford CA, Rosenberg MP, Vail DM, Williams LE, Cronin KL, Wilson-Robles H, Borgatti A, Henry CJ, Bailey DB, Locke J, Northrup NC, Crawford-Jakubiak M, Gill VL, Klein MK, Ruslander DM, Thamm DH, Phillips B, Post G.

PLoS One. 2015 Apr 29;10(4):e0124889. doi: 10.1371/journal.pone.0124889. eCollection 2015.

15.

Veterinary oncology clinical trials: design and implementation.

Thamm DH, Vail DM.

Vet J. 2015 Aug;205(2):226-32. doi: 10.1016/j.tvjl.2014.12.013. Epub 2014 Dec 19. Review.

PMID:
25582798
16.

Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs.

Mullin CM, Arkans MA, Sammarco CD, Vail DM, Britton BM, Vickery KR, Risbon RE, Lachowicz J, Burgess KE, Manley CA, Clifford CA.

Vet Comp Oncol. 2016 Dec;14(4):e171-e183. doi: 10.1111/vco.12131. Epub 2014 Dec 18.

PMID:
25524594
17.

Hypofractionated radiation therapy for the treatment of microscopic canine soft tissue sarcoma.

Kung MBJ, Poirier VJ, Dennis MM, Vail DM, Straw RC.

Vet Comp Oncol. 2016 Dec;14(4):e135-e145. doi: 10.1111/vco.12121. Epub 2014 Nov 13.

PMID:
25393921
18.

Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma.

Morges MA, Burton JH, Saba CF, Vail DM, Burgess KE, Thamm DH.

J Vet Intern Med. 2014 Sep-Oct;28(5):1569-74. doi: 10.1111/jvim.12429.

19.

Neurokinin-1 receptor expression and antagonism by the NK-1R antagonist maropitant in canine melanoma cell lines and primary tumour tissues.

Borrego JF, Huelsmeyer MK, Pinkerton ME, Muszynski JL, Miller SA, Kurzman ID, Vail DM.

Vet Comp Oncol. 2016 Jun;14(2):210-24. doi: 10.1111/vco.12093. Epub 2014 Apr 22.

PMID:
24751104
20.

Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.

Pan X, Tsimbas K, Kurzman ID, Vail DM.

Vet Comp Oncol. 2016 Jun;14(2):202-9. doi: 10.1111/vco.12091. Epub 2014 Apr 16.

PMID:
24735385
21.

GS-9219/VDC-1101--a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma.

Thamm DH, Vail DM, Kurzman ID, Babusis D, Ray AS, Sousa-Powers N, Tumas DB.

BMC Vet Res. 2014 Jan 25;10:30. doi: 10.1186/1746-6148-10-30.

22.

Comparative gene expression profiling identifies common molecular signatures of NF-κB activation in canine and human diffuse large B cell lymphoma (DLBCL).

Mudaliar MA, Haggart RD, Miele G, Sellar G, Tan KA, Goodlad JR, Milne E, Vail DM, Kurzman I, Crowther D, Argyle DJ.

PLoS One. 2013 Sep 4;8(9):e72591. doi: 10.1371/journal.pone.0072591. eCollection 2013.

23.

DNA repair deficiency as a susceptibility marker for spontaneous lymphoma in golden retriever dogs: a case-control study.

Thamm DH, Grunerud KK, Rose BJ, Vail DM, Bailey SM.

PLoS One. 2013 Jul 23;8(7):e69192. doi: 10.1371/journal.pone.0069192. Print 2013.

24.

Levels of evidence in canine oncology trials--a case in point.

Vail DM.

Vet Comp Oncol. 2013 Sep;11(3):167-8. doi: 10.1111/vco.12058. No abstract available.

PMID:
23909995
25.

Novel acyclic nucleotide analogues GS-343074 and GS-424044 demonstrate antiproliferative and pro-apoptotic activity in canine neoplastic cell lines.

Lawrence JA, Huelsmeyer MK, Thamm DH, Tumas DB, Birkus G, Kurzman I, Vail DM.

Vet Comp Oncol. 2015 Sep;13(3):246-54. doi: 10.1111/vco.12038. Epub 2013 May 15.

26.

Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document.

Nguyen SM, Thamm DH, Vail DM, London CA.

Vet Comp Oncol. 2015 Sep;13(3):176-83. doi: 10.1111/vco.12032. Epub 2013 Mar 28.

PMID:
23534501
27.

Comparative oncology - the North American experience.

Vail DM.

BMC Proc. 2013 Apr 4;7 Suppl 2:K5. doi: 10.1186/1753-6561-7-S2-K5. eCollection 2013. No abstract available.

28.

Efficacy and toxicity of an accelerated hypofractionated radiation therapy protocol in cats with oral squamous cell carcinoma.

Poirier VJ, Kaser-Hotz B, Vail DM, Straw RC.

Vet Radiol Ultrasound. 2013 Jan-Feb;54(1):81-8. doi: 10.1111/j.1740-8261.2012.01970.x. Epub 2012 Oct 19.

PMID:
23078236
29.

Phase I study to determine the maximal tolerated dose and dose-limiting toxicities of orally administered idarubicin in dogs with lymphoma.

Vail DM, Husbands BD, Kamerling SG, Simpson H, Kurzman ID, McDonnell A.

J Vet Intern Med. 2012 May-Jun;26(3):608-13. doi: 10.1111/j.1939-1676.2012.00896.x. Epub 2012 Mar 9.

30.

A randomized trial investigating the efficacy and safety of water soluble micellar paclitaxel (Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs.

Vail DM, von Euler H, Rusk AW, Barber L, Clifford C, Elmslie R, Fulton L, Hirschberger J, Klein M, London C, Martano M, McNiel EA, Morris JS, Northrup N, Phillips B, Polton G, Post G, Rosenberg M, Ruslander D, Sahora A, Siegel S, Thamm D, Westberg S, Winter J, Khanna C.

J Vet Intern Med. 2012 May-Jun;26(3):598-607. doi: 10.1111/j.1939-1676.2012.00897.x. Epub 2012 Mar 6.

31.

Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.

London C, Mathie T, Stingle N, Clifford C, Haney S, Klein MK, Beaver L, Vickery K, Vail DM, Hershey B, Ettinger S, Vaughan A, Alvarez F, Hillman L, Kiselow M, Thamm D, Higginbotham ML, Gauthier M, Krick E, Phillips B, Ladue T, Jones P, Bryan J, Gill V, Novasad A, Fulton L, Carreras J, McNeill C, Henry C, Gillings S.

Vet Comp Oncol. 2012 Sep;10(3):194-205. doi: 10.1111/j.1476-5829.2011.00275.x. Epub 2011 Jun 1.

32.

Phase II clinical evaluation of lomustine chemotherapy for feline vaccine-associated sarcoma.

Saba CF, Vail DM, Thamm DH.

Vet Comp Oncol. 2012 Dec;10(4):283-91. doi: 10.1111/j.1476-5829.2011.00295.x. Epub 2011 Oct 17.

PMID:
22236148
33.

Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.

Chon E, McCartan L, Kubicek LN, Vail DM.

Vet Comp Oncol. 2012 Sep;10(3):184-93. doi: 10.1111/j.1476-5829.2011.00265.x. Epub 2011 Mar 21.

PMID:
22235941
34.

Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.

Robat C, London C, Bunting L, McCartan L, Stingle N, Selting K, Kurzman I, Vail DM.

Vet Comp Oncol. 2012 Sep;10(3):174-83. doi: 10.1111/j.1476-5829.2011.00261.x. Epub 2011 Jan 31.

35.

Intravenous administration of docetaxel to cats with cancer.

Shiu KB, McCartan L, Kubicek L, Vail DM.

J Vet Intern Med. 2011 Jul-Aug;25(4):916-9. doi: 10.1111/j.1939-1676.2011.0734.x. Epub 2011 May 25.

36.

Proof of principle of ocular sparing in dogs with sinonasal tumors treated with intensity-modulated radiation therapy.

Lawrence JA, Forrest LJ, Turek MM, Miller PE, Mackie TR, Jaradat HA, Vail DM, Dubielzig RR, Chappell R, Mehta MP.

Vet Radiol Ultrasound. 2010 Sep-Oct;51(5):561-70.

37.

Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs.

Paoloni MC, Mazcko C, Fox E, Fan T, Lana S, Kisseberth W, Vail DM, Nuckolls K, Osborne T, Yalkowsy S, Gustafson D, Yu Y, Cao L, Khanna C.

PLoS One. 2010 Jun 8;5(6):e11013. doi: 10.1371/journal.pone.0011013.

38.

Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document.

Vail DM, Michels GM, Khanna C, Selting KA, London CA; Veterinary Cooperative Oncology Group.

Vet Comp Oncol. 2010 Mar;8(1):28-37. doi: 10.1111/j.1476-5829.2009.00200.x.

PMID:
20230579
39.

Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation.

Thamm DH, Kurzman ID, Clark MA, Ehrhart EJ 3rd, Kraft SL, Gustafson DL, Vail DM.

Clin Cancer Res. 2010 Mar 1;16(5):1498-508. doi: 10.1158/1078-0432.CCR-09-2804. Epub 2010 Feb 16.

40.

Use of 3'-deoxy-3'-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma.

Lawrence J, Vanderhoek M, Barbee D, Jeraj R, Tumas DB, Vail DM.

Vet Radiol Ultrasound. 2009 Nov-Dec;50(6):660-8.

PMID:
19999354
41.

Supporting the veterinary cancer patient on chemotherapy: neutropenia and gastrointestinal toxicity.

Vail DM.

Top Companion Anim Med. 2009 Aug;24(3):122-9. doi: 10.1053/j.tcam.2009.02.004. Review.

PMID:
19732730
42.

Medline acceptance and impact factor assignment.

Argyle DJ, Vail DM.

Vet Comp Oncol. 2009 Sep;7(3):151-2. doi: 10.1111/j.1476-5829.2009.00195.x. No abstract available.

PMID:
19691643
43.

Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma.

Saba CF, Hafeman SD, Vail DM, Thamm DH.

J Vet Intern Med. 2009 Sep-Oct;23(5):1058-63. doi: 10.1111/j.1939-1676.2009.0357.x. Epub 2009 Aug 11.

44.

Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma.

Vail DM, Thamm DH, Reiser H, Ray AS, Wolfgang GH, Watkins WJ, Babusis D, Henne IN, Hawkins MJ, Kurzman ID, Jeraj R, Vanderhoek M, Plaza S, Anderson C, Wessel MA, Robat C, Lawrence J, Tumas DB.

Clin Cancer Res. 2009 May 15;15(10):3503-10. doi: 10.1158/1078-0432.CCR-08-3113. Epub 2009 May 5.

45.

Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcoma.

Thamm DH, O'Brien MG, Vail DM.

Vet Comp Oncol. 2008 Jun;6(2):126-32. doi: 10.1111/j.1476-5829.2007.00153.x.

PMID:
19178672
46.

Dose-escalating vinblastine for the treatment of canine mast cell tumour.

Vickery KR, Wilson H, Vail DM, Thamm DH.

Vet Comp Oncol. 2008 Jun;6(2):111-9. doi: 10.1111/j.1476-5829.2007.00147.x.

PMID:
19178670
47.

Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs.

Phillips B, Powers BE, Dernell WS, Straw RC, Khanna C, Hogge GS, Vail DM.

J Am Anim Hosp Assoc. 2009 Jan-Feb;45(1):33-8.

PMID:
19122062
48.

Phase I clinical evaluation of carboplatin in tumor-bearing cats: a Veterinary Cooperative Oncology Group study.

Kisseberth WC, Vail DM, Yaissle J, Jeglum KA, Couto CG, Ward H, Khanna C, Obradovich JE.

J Vet Intern Med. 2008 Jan-Feb;22(1):83-8. doi: 10.1111/j.1939-1676.2007.0017.x.

49.

Human granulocyte-macrophage colony-stimulating factor DNA cationic-lipid complexed autologous tumour cell vaccination in the treatment of canine B-cell multicentric lymphoma.

Turek MM, Thamm DH, Mitzey A, Kurzman ID, Huelsmeyer MK, Dubielzig RR, Vail DM.

Vet Comp Oncol. 2007 Dec;5(4):219-31. doi: 10.1111/j.1476-5829.2007.00128.x.

PMID:
19754780
50.

Cancer clinical trials: development and implementation.

Vail DM.

Vet Clin North Am Small Anim Pract. 2007 Nov;37(6):1033-57; v. Review.

PMID:
17950881

Supplemental Content

Support Center